{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:15:01Z","timestamp":1783401301887,"version":"3.54.6"},"reference-count":185,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Human papillomavirus (HPV)-associated cancers provide a unique model for understanding the paradox of viral antigenicity and tumor immune escape. Although viral oncoproteins such as E6 and E7 generate non-self antigens, many HPV-associated tumors persist under immune pressure and show heterogeneous responses to immune checkpoint blockade. This discrepancy reflects a process in which persistent HPV infection and malignant transformation remodel innate immune sensing, interferon (IFN) signaling, antigen presentation, and the tumor microenvironment. These changes impair dendritic cell activation and cytotoxic immune priming while promoting chronic inflammation, myeloid polarization, T-cell exhaustion, and PD-1\/PD-L1-mediated adaptive immune resistance. In this review, we discuss how HPV-associated cancers subvert antiviral innate immunity and how these processes contribute to immune evasion. We further highlight therapeutic strategies aimed at restoring antiviral antitumor immunity, including immune checkpoint blockade, STING agonists, therapeutic HPV vaccines, radiotherapy-based combinations, TGF-\u03b2 pathway inhibition, and biomarker-guided treatment approaches. Understanding the links among viral pathogenesis, innate immune remodeling, and checkpoint evasion may support more rational immunotherapy combinations for HPV-associated malignancies.<\/jats:p>","DOI":"10.3389\/fcimb.2026.1875111","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:23:57Z","timestamp":1783398237000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting innate immunity to overcome immune evasion in HPV-associated cancers"],"prefix":"10.3389","volume":"16","author":[{"given":"Xianguang","family":"Bai","sequence":"first","affiliation":[{"name":"School of Medical Science and Technology, Pingdingshan University","place":["Pingdingshan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Dai","sequence":"additional","affiliation":[{"name":"School of Medicine, Pingdingshan University","place":["Pingdingshan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zebao","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Medical Technology, Chuxiong Medical College","place":["Chuxiong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Laboratory of Immunity, Inflammation & Cancer, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7520","DOI":"10.1158\/0008-5472.can-08-1060","article-title":"Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo","volume":"68","author":"Ahmadi","year":"2008","journal-title":"Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/19336918.2015.1042197","article-title":"E5 and E6\/E7 of high-risk HPVs cooperate to enhance cancer progression through EMT initiation","volume":"9","author":"Al Moustafa","year":"2015","journal-title":"Cell. Adh Migr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/jci91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1128\/jvi.76.1.280-291.2002","article-title":"Disturbance of tumor necrosis factor alpha-mediated beta interferon signaling in cervical carcinoma cells","volume":"76","author":"Bachmann","year":"2002","journal-title":"J. Virol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ijrobp.2018.06.295","article-title":"Chromosomal instability drives metastasis through a cytosolic DNA response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell."},{"key":"B9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijrobp.2023.11.050","article-title":"Radiation therapy and myeloid-derived suppressor cells: Breaking down their cancerous partnership","volume":"119","author":"Bergerud","year":"2024","journal-title":"Int. J. Radiat Oncol. Biol. Phys."},{"key":"B10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1001\/jamaoncol.2024.2145","article-title":"Bintrafusp alfa for recurrent or metastatic cervical cancer after platinum failure: a nonrandomized controlled trial","volume":"10","author":"Birrer","year":"2024","journal-title":"JAMA Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tim.2010.10.002","article-title":"Persistence of human papillomavirus infection: Keys to Malignant progression","volume":"19","author":"Bodily","year":"2011","journal-title":"Trends Microbiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1158\/1078-0432.ccr-24-0385","article-title":"Cervical cancer evades the host immune system through the inhibition of type I interferon and CXCL9 by LIF","volume":"30","author":"Bonfill-Teixidor","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jmii.2020.07.010","article-title":"Loss of HPV type 16 E7 restores cGAS-STING responses in human papilloma virus-positive oropharyngeal squamous cell carcinomas cells","volume":"54","author":"Bortnik","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.immuni.2024.03.014","article-title":"Control of adaptive immunity by pattern recognition receptors","volume":"57","author":"Carroll","year":"2024","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.3390\/biomedicines10112965","article-title":"Alteration of the IFN-pathway by human papillomavirus proteins: antiviral immune response evasion mechanism","volume":"10","author":"Castro-Mu\u00f1oz","year":"2022","journal-title":"Biomedicines"},{"key":"B17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2022.105929","article-title":"Chlamydia trachomatis infection co-operatively enhances HPV E6-E7 oncogenes mediated tumorigenesis and immunosuppression","volume":"175","author":"Challagundla","year":"2023","journal-title":"Microb. Pathog."},{"key":"B19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111647","article-title":"Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8(+) T cell exhaustion and curtails anti-PD-1 efficacy","volume":"41","author":"Chen","year":"2022","journal-title":"Cell Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"9934","DOI":"10.1038\/s41467-024-54293-z","article-title":"Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy","volume":"15","author":"Choi","year":"2024","journal-title":"Nat. Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-023-02371-y","article-title":"Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance","volume":"29","author":"Chu","year":"2023","journal-title":"Nat. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.0900092","article-title":"Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells","volume":"182","author":"Corzo","year":"2009","journal-title":"J. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/sj.bjc.6605611","article-title":"Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia","volume":"102","author":"Daayana","year":"2010","journal-title":"Br. J. Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","article-title":"TGF-\u03b2 signaling in health, disease, and therapeutics","volume":"9","author":"Deng","year":"2024","journal-title":"Signal. Transd Targ Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J. Exp. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1038\/s41467-024-48073-y","article-title":"TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in Malignant glioma: a randomized phase II Trial","volume":"15","author":"Everson","year":"2024","journal-title":"Nat. Commun."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2013598118","article-title":"Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma","volume":"118","author":"Falahat","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1158\/1078-0432.ccr-22-0346","article-title":"SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, for recurrent or metastatic cervical cancer: a clinical expansion cohort of a phase I study","volume":"28","author":"Feng","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006714","article-title":"Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity","volume":"11","author":"Fernandez-Rodriguez","year":"2023","journal-title":"J. ImmunoTher Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/cancers12030646","article-title":"The interplay between antiviral signalling and carcinogenesis in human papillomavirus infections","volume":"12","author":"Ferreira","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1001\/jamaoncol.2018.1888","article-title":"Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: the active8 randomized clinical trial","volume":"4","author":"Ferris","year":"2018","journal-title":"JAMA Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"283ra52","DOI":"10.1126\/scitranslmed.aaa4306","article-title":"STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade","volume":"7","author":"Fu","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1498439","article-title":"Treatment-na\u00efve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy","volume":"7","author":"Gameiro","year":"2018","journal-title":"Oncoimmunology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.18632\/oncotarget.1719","article-title":"Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing","volume":"5","author":"Gameiro","year":"2014","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.795401","article-title":"The cGAS\/STING\u2002pathway: A novel target for cancer therapy","volume":"12","author":"Gan","year":"2021","journal-title":"Front. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 Pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2022.07.021","article-title":"Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-54596-2_910","article-title":"TGF-\u03b2RII\/IL-15 immunotherapeutic complex targets exhausted CD8(+) T-cell subsets in lymph nodes and tumors","volume":"13","author":"George","year":"2025","journal-title":"J. ImmunoTher Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1084\/jem.20050463","article-title":"Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation","volume":"202","author":"Ghiringhelli","year":"2005","journal-title":"J. Exp. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2005-05-1795","article-title":"Tumor-derived lactic acid modulates dendritic cell activation and antigen expression","volume":"107","author":"Gottfried","year":"2006","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3390\/v13071390","article-title":"Human papillomaviruses target the DNA damage repair and innate immune response pathways to allow for persistent infection","volume":"13","author":"Gusho","year":"2021","journal-title":"Viruses"},{"key":"B47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/01.ogx.0001050544.16643.94","article-title":"Clinical validation of human papilloma virus circulating tumor DNA for early detection of residual disease after chemoradiation in cervical cancer","volume":"42","author":"Han","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.cd-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.18632\/oncotarget.27992","article-title":"Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent\/metastatic head and neck squamous cell carcinoma","volume":"12","author":"Haring","year":"2021","journal-title":"Oncotarget"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.4049\/jimmunol.178.5.3186","article-title":"TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16","volume":"178","author":"Hasan","year":"2007","journal-title":"J. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1084\/jem.20122394","article-title":"The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter","volume":"210","author":"Hasan","year":"2013","journal-title":"J. Exp. Med."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044952","article-title":"Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women","volume":"7","author":"Hasim","year":"2012","journal-title":"PloS One"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.ccr-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.oraloncology.2018.05.010","article-title":"Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1","volume":"82","author":"Hlad\u00edkov\u00e1","year":"2018","journal-title":"Oral. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.tim.2017.07.007","article-title":"The HPV E6\/E7 oncogenes: Key factors for viral carcinogenesis and therapeutic targets","volume":"26","author":"Hoppe-Seyler","year":"2018","journal-title":"Trends Microbiol."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.849352","article-title":"PD-1\/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed","volume":"12","author":"Huang","year":"2022","journal-title":"Front. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/ni.3123","article-title":"Control of adaptive immunity by the innate immune system","volume":"16","author":"Iwasaki","year":"2015","journal-title":"Nat. Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"14113","DOI":"10.1073\/pnas.1903520116","article-title":"Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade","volume":"116","author":"Jadhav","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00828-19","article-title":"Human papillomavirus 16 E6 and E7 synergistically repress innate immune gene transcription","volume":"5","author":"James","year":"2020","journal-title":"mSphere"},{"key":"B61","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/v16050680","article-title":"Human papillomavirus and associated cancers: A review","volume":"16","author":"Jensen","year":"2024","journal-title":"Viruses"},{"key":"B62","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s40425-019-0573-5","article-title":"STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models","volume":"7","author":"Jing","year":"2019","journal-title":"J. ImmunoTher Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1182\/blood-2008-12-195073","article-title":"Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells","volume":"114","author":"J\u00fcrgens","year":"2009","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1007\/s00262-023-03571-8","article-title":"HPV-associated head and neck cancer is characterized by distinct profiles of CD8(+) T cells and myeloid-derived suppressor cells","volume":"72","author":"Kansy","year":"2023","journal-title":"Cancer Immunol. Immunother"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003384","article-title":"Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response","volume":"9","author":"Karim","year":"2013","journal-title":"PloS Pathog."},{"key":"B67","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s12276-021-00602-1","article-title":"Innate immune sensing of coronavirus and viral evasion strategies","volume":"53","author":"Kasuga","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2022.102172","article-title":"Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics","volume":"70","author":"Kaur","year":"2022","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1158\/1078-0432.ccr-07-1881","article-title":"Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity","volume":"14","author":"Kenter","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2011.00075","article-title":"Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens","volume":"2","author":"Keskin","year":"2011","journal-title":"Front. Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1038\/s41467-021-23244-3","article-title":"PLGA-particle vaccine carrying TLR3\/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy","volume":"12","author":"Koerner","year":"2021","journal-title":"Nat. Commun."},{"key":"B72","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.1158\/0008-5472.can-18-0163","article-title":"Human papilloma virus specific immunogenicity and dysfunction of CD8(+) T cells in head and neck cancer","volume":"78","author":"Krishna","year":"2018","journal-title":"Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"989","DOI":"10.4049\/jimmunol.172.2.989","article-title":"Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species","volume":"172","author":"Kusmartsev","year":"2004","journal-title":"J. Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.cd-19-0761","article-title":"The cytosolic DNA-sensing cGAS-STING pathway in cancer","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discov."},{"key":"B75","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1016\/j.cell.2021.09.019","article-title":"Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment","volume":"184","author":"Lam","year":"2021","journal-title":"Cell."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004122","article-title":"Colocalized targeting of TGF-\u03b2 and PD-L1 by bintrafusp alfa elicits distinct antitumor responses","volume":"10","author":"Lan","year":"2022","journal-title":"J. ImmunoTher Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1126\/science.aab3291","article-title":"DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway","volume":"350","author":"Lau","year":"2015","journal-title":"Science"},{"key":"B78","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29386","article-title":"Deciphering head and neck cancer microenvironment: Single-cell and spatial transcriptomics reveals human papillomavirus-associated differences","volume":"96","author":"Lee","year":"2024","journal-title":"J. Med. Virol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1097\/01.ogx.0000733532.83957.5b","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00241-8","article-title":"Cancer vaccines: platforms and current progress","volume":"6","author":"Lei","year":"2025","journal-title":"Mol. Biomed."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/jnci\/djt184","article-title":"MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells","volume":"105","author":"Leone","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1195476","article-title":"The anti-PD-1 era of cervical cancer: Achievement, opportunity, and challenge","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41586-023-06464-z","article-title":"Non-cell-autonomous cancer progression from chromosomal instability","volume":"620","author":"Li","year":"2023","journal-title":"Nature"},{"key":"B85","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41586-020-2850-3","article-title":"Cancer immunotherapy via targeted TGF-\u03b2 signalling blockade in T(H) cells","volume":"587","author":"Li","year":"2020","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal. Transd Targ Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","article-title":"Pattern recognition receptors in health and diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal. Transd Targ Ther."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1342647","article-title":"STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216318","article-title":"The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells","volume":"569","author":"Lin","year":"2023","journal-title":"Cancer Lett."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3892\/mmr.2016.6073","article-title":"Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity","volume":"15","author":"Liu","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"B91","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jare.2024.12.043","article-title":"Targeting macrophages in cancer immunotherapy: Frontiers and challenges","volume":"76","author":"Liu","year":"2025","journal-title":"J. Adv. Res."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00065","article-title":"PD-1\/PD-L1 inhibitors in cervical cancer","volume":"10","author":"Liu","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/pathogens9040292","article-title":"Subversion of host innate immunity by human papillomavirus oncoproteins","volume":"9","author":"Lo Cigno","year":"2020","journal-title":"Pathogens"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/s0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28310","article-title":"DNA virus oncoprotein HPV18 E7 selectively antagonizes cGAS-STING-triggered innate immune activation","volume":"95","author":"Lou","year":"2023","journal-title":"J. Med. Virol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00262-017-2029-4","article-title":"Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-\u03b3 and multiple toll-like receptor agonists","volume":"66","author":"L\u00f6vgren","year":"2017","journal-title":"Cancer Immunol. Immunother"},{"key":"B97","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ccell.2022.04.009","article-title":"Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition","volume":"40","author":"Low","year":"2022","journal-title":"Cancer Cell."},{"key":"B98","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.oraloncology.2018.01.019","article-title":"STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV(+) status in head and neck cancer","volume":"78","author":"Lu","year":"2018","journal-title":"Oral. Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41422-020-00395-4","article-title":"Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy","volume":"30","author":"Lv","year":"2020","journal-title":"Cell Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1158\/0008-5472.can-12-2384","article-title":"Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma","volume":"73","author":"Lyford-Pike","year":"2013","journal-title":"Cancer Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature23449","article-title":"cGAS surveillance of micronuclei links genome instability to innate immunity","volume":"548","author":"Mackenzie","year":"2017","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.3390\/ijms24119543","article-title":"Oncogenic viruses and the epigenome: How viruses hijack epigenetic mechanisms to drive cancer","volume":"24","author":"MacLennan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B103","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.virol.2011.10.012","article-title":"Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation","volume":"422","author":"Magaldi","year":"2012","journal-title":"Virology"},{"key":"B104","doi-asserted-by":"publisher","first-page":"8163","DOI":"10.2174\/0929867327666201111145546","article-title":"E6 and E7 oncoproteins: Potential targets of cervical cancer","volume":"28","author":"Malla","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"B105","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1186\/s12967-025-07280-x","article-title":"Spatial profiling of HPV-stratified head and neck squamous cell carcinoma reveals distinct immune niches and microenvironmental architectures","volume":"23","author":"Markovits","year":"2025","journal-title":"J. Transl. Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"8378","DOI":"10.1128\/jvi.77.15.8378-8385.2003","article-title":"Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin","volume":"77","author":"Matthews","year":"2003","journal-title":"J. Virol."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00262-007-0362-8","article-title":"Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma","volume":"57","author":"Mehta","year":"2008","journal-title":"Cancer Immunol. Immunother"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"B112","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41564-019-0421-x","article-title":"Decoding type I and III interferon signalling during viral infection","volume":"4","author":"Mesev","year":"2019","journal-title":"Nat. Microbiol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/modpathol.2015.108","article-title":"Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers","volume":"28","author":"Mezache","year":"2015","journal-title":"Mod. Pathol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/s1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/jco.19.00739","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ccell.2015.03.015","article-title":"Radiotherapy complements immune checkpoint blockade","volume":"27","author":"Ngiow","year":"2015","journal-title":"Cancer Cell."},{"key":"B118","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.bioactmat.2024.09.002","article-title":"STING-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy","volume":"42","author":"Nguyen","year":"2024","journal-title":"Bioact Mater."},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk3160","article-title":"Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade","volume":"17","author":"Nishinakamura","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012728","article-title":"HPV-positive HNSCC and Fc-silent PD-1 blockade: A clinical discrepancy that raises next immunological questions","volume":"13","author":"Okuyama","year":"2025","journal-title":"J. ImmunoTher Cancer"},{"key":"B121","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jiph.2023.02.014","article-title":"Human papillomavirus in cancer: Infection, disease transmission, and progress in vaccines","volume":"16","author":"Oyouni","year":"2023","journal-title":"J. Infect. Public Health"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba6098","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"Pan","year":"2020","journal-title":"Science"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.965570","article-title":"Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma","volume":"4","author":"Partlov\u00e1","year":"2015","journal-title":"Oncoimmunology"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"B125","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/s1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41417-023-00682-3","article-title":"HPV E6\/E7: Insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor","volume":"31","author":"Peng","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01875-21","article-title":"High-risk mucosal human papillomavirus 16 (HPV16) E6 protein and cutaneous HPV5 and HPV8 E6 proteins employ distinct strategies to interfere with interferon regulatory factor 3-mediated beta interferon expression","volume":"96","author":"Poirson","year":"2022","journal-title":"J. Virol."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009803","article-title":"Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses","volume":"12","author":"Pulliam","year":"2024","journal-title":"J. ImmunoTher Cancer"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008480","article-title":"Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with advanced non-small cell lung cancer","volume":"12","author":"Rajan","year":"2024","journal-title":"J. ImmunoTher Cancer"},{"key":"B130","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/cji.0b013e318279652e","article-title":"Human papillomavirus type 16 E6\/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated Malignancies","volume":"36","author":"Ramos","year":"2013","journal-title":"J. Immunother"},{"key":"B131","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/jnci\/djp017","article-title":"E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells","volume":"101","author":"Rampias","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3390\/v14071361","article-title":"Human beta papillomavirus type 8 E1 and E2 proteins suppress the activation of the RIG-I-like receptor MDA5","volume":"14","author":"Rattay","year":"2022","journal-title":"Viruses"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009613","article-title":"TGF-\u03b2 trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance","volume":"12","author":"Reid","year":"2024","journal-title":"J. ImmunoTher Cancer"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J. Exp. Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"6327","DOI":"10.1038\/s41388-020-01431-8","article-title":"HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers","volume":"39","author":"Ren","year":"2020","journal-title":"Oncogene"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1101\/gad.12.13.2061","article-title":"Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity","volume":"12","author":"Ronco","year":"1998","journal-title":"Genes Dev."},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.596825","article-title":"PD-L1 and PD-L2 expression in cervical cancer: Regulation and biomarker potential","volume":"11","author":"Rotman","year":"2020","journal-title":"Front. Immunol."},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93397","article-title":"Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer","volume":"2","author":"Sato-Kaneko","year":"2017","journal-title":"JCI Insight"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/2159-8290.cd-20-1760","article-title":"Tumor immunity and immunotherapy for HPV-related cancers","volume":"11","author":"Shamseddine","year":"2021","journal-title":"Cancer Discov."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28220","article-title":"SARS-CoV-2, HIV, and HPV: Convergent evolution of selective regulation of cGAS-STING signaling","volume":"95","author":"Shen","year":"2023","journal-title":"J. Med. Virol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1158\/0008-5472.can-12-2083","article-title":"Inactivating all three rb family pocket proteins is insufficient to initiate cervical cancer","volume":"72","author":"Shin","year":"2012","journal-title":"Cancer Res."},{"key":"B142","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ijrobp.2021.05.014","article-title":"Regulatory T cells shape the differential impact of radiation dose-fractionation schedules on host innate and adaptive antitumor immune defenses","volume":"111","author":"Sia","year":"2021","journal-title":"Int. J. Radiat Oncol. Biol. Phys."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1080\/21645515.2015.1136039","article-title":"Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases","volume":"12","author":"Skeate","year":"2016","journal-title":"Hum. Vaccin Immunother"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3390\/pathogens11091027","article-title":"Do or die: HPV E5, E6 and E7 in cell death evasion","volume":"11","author":"Skelin","year":"2022","journal-title":"Pathogens"},{"key":"B145","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ccell.2025.02.014","article-title":"Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy","volume":"43","author":"Song","year":"2025","journal-title":"Cancer Cell."},{"key":"B146","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3892\/ol.2015.3295","article-title":"Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer","volume":"10","author":"Song","year":"2015","journal-title":"Oncol. Lett."},{"key":"B147","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/0008-5472.can-09-2587","article-title":"Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine","volume":"70","author":"Srivastava","year":"2010","journal-title":"Cancer Res."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.celrep.2017.05.015","article-title":"A TLR3-specific adjuvant relieves innate resistance to PD-L1 blockade without cytokine toxicity in tumor vaccine immunotherapy","volume":"19","author":"Takeda","year":"2017","journal-title":"Cell Rep."},{"key":"B149","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"B150","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"B151","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/01.ogx.0000834600.51705.68","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B152","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell."},{"key":"B153","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13046-022-02481-4","article-title":"The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-na\u00efve tumors with immune checkpoint inhibitors","volume":"41","author":"Tosi","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B154","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"B155","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat. Commun."},{"key":"B157","doi-asserted-by":"publisher","first-page":"20180287","DOI":"10.1098\/rstb.2018.0287","article-title":"Cross-talk of cutaneous beta human papillomaviruses and the immune system: Determinants of disease penetrance","volume":"374","author":"Venuti","year":"2019","journal-title":"Philos. Trans. R. Soc Lond. B. Biol. Sci."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41586-025-09539-1","article-title":"Proteotoxic stress response drives T cell exhaustion and immune evasion","volume":"647","author":"Wang","year":"2025","journal-title":"Nature"},{"key":"B159","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12964-025-02169-0","article-title":"Unveiling the crossroads of STING signaling pathway and metabolic reprogramming: the multifaceted role of the STING in the TME and new prospects in cancer therapies","volume":"23","author":"Wang","year":"2025","journal-title":"Cell. Commun. Signal."},{"key":"B160","doi-asserted-by":"publisher","first-page":"13404","DOI":"10.1038\/s41598-019-49771-0","article-title":"HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1485546","article-title":"Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/v15071440","article-title":"Recent developments in human papillomavirus (HPV) vaccinology","volume":"15","author":"Williamson","year":"2023","journal-title":"Viruses"},{"key":"B163","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl6173","article-title":"Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity","volume":"385","author":"Wu","year":"2024","journal-title":"Science"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/med.21649","article-title":"Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy","volume":"40","author":"Wu","year":"2020","journal-title":"Med. Res. Rev."},{"key":"B166","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/ijms22010379","article-title":"LAG-3, TIM-3 and VISTA expression on tumor-infiltrating lymphocytes in oropharyngeal squamous cell carcinoma-potential biomarkers for targeted therapy concepts","volume":"22","author":"Wuerdemann","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B167","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41416-020-0966-8","article-title":"Fewer tumour-specific PD-1(+)CD8(+) TILs in high-risk \"Infiltrating\" HPV(-) HNSCC","volume":"123","author":"Xu","year":"2020","journal-title":"Br. J. Cancer"},{"key":"B168","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jconrel.2024.05.042","article-title":"A next-generation STING agonist MSA-2: From mechanism to application","volume":"371","author":"Yang","year":"2024","journal-title":"J. Ctrl Rel"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41467-026-69456-3","article-title":"Triple targeting of STING, TGF-\u03b2, and PD-L1 boosts CXCL16-CXCR6 signaling for potent antitumor response","volume":"17","author":"Yi","year":"2026","journal-title":"Nat. Commun."},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202408598","article-title":"Blockade of CCR5(+) T cell accumulation in the tumor microenvironment optimizes anti-TGF-\u03b2\/PD-L1 bispecific antibody","volume":"11","author":"Yi","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"B171","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-022-01363-8","article-title":"Combination of oral STING agonist MSA-2 and anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors","volume":"15","author":"Yi","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13045-021-01155-6","article-title":"Combine and conquer: manganese synergizing anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005543","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer","volume":"10","author":"Yi","year":"2022","journal-title":"J. ImmunoTher Cancer"},{"key":"B174","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","article-title":"The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adw3571","article-title":"Enhanced FOS expression improves tumor clearance and resists exhaustion in NR4A3-deficient CAR T cells under chronic antigen exposure","volume":"11","author":"Yin","year":"2025","journal-title":"Sci. Adv."},{"key":"B176","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ni1087","article-title":"The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses","volume":"5","author":"Yoneyama","year":"2004","journal-title":"Nat. Immunol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/s1470-2045(20)30486-1","article-title":"Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial","volume":"21","author":"Youn","year":"2020","journal-title":"Lancet Oncol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.canlet.2020.10.034","article-title":"HPV post-infection microenvironment and cervical cancer","volume":"497","author":"Yuan","year":"2021","journal-title":"Cancer Lett."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41556-023-01185-x","article-title":"STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2","volume":"25","author":"Zhang","year":"2023","journal-title":"Nat. Cell Biol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41467-023-37328-9","article-title":"STING agonist-loaded, CD47\/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005158","article-title":"Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: A systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2022","journal-title":"J. ImmunoTher Cancer"},{"key":"B182","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1099\/vir.0.054486-0","article-title":"Human papillomavirus 16-encoded E7 protein inhibits IFN-\u03b3-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes","volume":"94","author":"Zhou","year":"2013","journal-title":"J. Gen. Virol."},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00682","article-title":"Papillomavirus immune evasion strategies target the infected cell and the local immune system","volume":"9","author":"Zhou","year":"2019","journal-title":"Front. Oncol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00005-013-0220-7","article-title":"Toll-like receptors in human papillomavirus infection","volume":"61","author":"Zhou","year":"2013","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)"},{"key":"B185","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jiph.2023.01.019","article-title":"Clinical significance of immune checkpoint proteins in HPV-infected cervical cancer","volume":"16","author":"Zou","year":"2023","journal-title":"J. Infect. Public Health"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1875111\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:23:59Z","timestamp":1783398239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1875111\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":185,"alternative-id":["10.3389\/fcimb.2026.1875111"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1875111","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1875111"}}